Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
-
Maria De Filippo [1] ; Martina Votto [1] ; Lucia Caminiti [2] ; Francesco Carella [4] ; Giovanna De Castro [3] ; Massimo Landi [5] ; Roberta Olcese [6] ; Ilenia Panasiti [2] ; Mario Vernich [7] ; Salvatore Barberi [7] ; Giorgio Ciprandi [8] ; Gian Luigi Marseglia [1]
-
[1] University of Pavia
University of Pavia
Pavía, Italia
-
[2] University of Messina
University of Messina
Mesina, Italia
-
[3] Università de Roma La Sapienza
Università de Roma La Sapienza
Roma Capitale, Italia
-
[4] Pediatric Unit, Azienza Ospedaliera Universitaria Policlinico Giovanni XXIII, Bari, Italy
-
[5] Pediatric National Healthcare System, Turin, Italy – Istituto di Biomedicina e Immunologia molecolare, Italian National Research Council, Palermo, Italy
-
[6] Department of Pediatrics, Allergy Center, Istituto Giannina Gaslini, Genoa, Italy.
-
[7] Pediatric Unit, ASST-Rhodense, RHO, Milan, Italy
-
[8] Allergy Clinic, Casa di cura Villa Montallegro, Genoa, Italy.
-
- Localización: Allergologia et immunopathologia: International journal for clinical and investigate allergology and clinical immunology, ISSN-e 1578-1267, ISSN 0301-0546, Vol. 50, Nº. 6, 2022, págs. 47-52
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Although currently approved to treat severe asthma and chronic spontaneous urticaria, omalizumab has also been an effective and safe add-on treatment for other allergic diseases. Namely, omalizumab has been proposed to be used as add-on therapy in patients with allergic rhinitis and asthma and undergoing specific allergen immunotherapy (AIT). AIT is the only treatment that modifies the natural history of IgE-mediated diseases. This brief review summarizes the available evidence and controversies on the efficacy and safety of omalizumab combined with specific AIT.
